▲ +3.12% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for McKesson in the last 3 months. The average price target is $185.62, with a high forecast of $222.00 and a low forecast of $165.00. The average price target represents a 3.12% upside from the last price of $180.00.
The current consensus among 13 investment analysts is to buy stock in McKesson. This Buy consensus rating has held steady for over two years.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and solutions for life sciences companies, including offering multiple distribution channels and clinical trial access to specific patient populations through its network of oncology physicians. The segment also sells financial, operational and clinical solutions to pharmacies; and offers consulting, outsourcing, and other services. The Prescription Technology Solutions segment operates in the healthcare delivery system to connect pharmacies, providers, payers, and biopharma for next-generation patient access and adherence solutions. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.